InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $2.370 0.1 (4.41%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$884 Clarity Half Yearly Report 28 Feb 2022 4:27PM $0.630 $2.370 risen by 276.19%
$884 Half Year Accounts 28 Feb 2022 3:54PM $0.635 $2.370 risen by 273.23%
$884 Update on China Grand Pharmaceutical and Healthcare Holdings 28 Feb 2022 9:54AM $0.650 $2.370 risen by 264.62%
$884 First patient treated in cohort 2 neuroblastoma trial 25 Feb 2022 9:28AM $0.660 $2.370 risen by 259.09%
$884 Release of Securities from Escrow 18 Feb 2022 11:02AM $0.735 $2.370 risen by 222.45%
$884 US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA 7 Feb 2022 9:44AM $0.720 $2.370 risen by 229.17%
$884 Clarity receives $3.26 million R&D tax incentive refund 4 Feb 2022 9:55AM $0.705 $2.370 risen by 236.17%
$884 Response to media reports of shortages of medical isotopes 3 Feb 2022 3:28PM $0.715 $2.370 risen by 231.47%
$884 SARTATE Neuroblastoma trial advances to cohort 2 1 Feb 2022 9:41AM $0.750 $2.370 risen by 216%
$884 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2022 3:45PM $0.775 $2.370 risen by 205.81%
$884 Becoming a substantial holder 12 Jan 2022 2:46PM $0.880 $2.370 risen by 169.32%
$884 Change of Director's Interest Notice - Biggin 4 Jan 2022 2:31PM $0.740 $2.370 risen by 220.27%
$884 Cleansing Notice 4 Jan 2022 2:25PM $0.740 $2.370 risen by 220.27%
$884 Application for quotation of securities - CU6 4 Jan 2022 2:22PM $0.740 $2.370 risen by 220.27%
$884 Becoming a substantial holder 30 Dec 2021 3:57PM $0.760 $2.370 risen by 211.84%
$884 Application for quotation of securities - CU6 30 Dec 2021 9:57AM $0.780 $2.370 risen by 203.85%
$884 Application for quotation of securities - CU6 29 Dec 2021 3:39PM $0.800 $2.370 risen by 196.25%
$884 Release of Securities from Escrow 7 Dec 2021 2:19PM $0.840 $2.370 risen by 182.14%
$884 Clarity and Cardinal Health enter into Agreement for TCT 2 Dec 2021 9:46AM $0.900 $2.370 risen by 163.33%
$884 Fifty percent recruitment milestone for PROPELLER trial 1 Dec 2021 1:11PM $0.925 $2.370 risen by 156.22%
$884 Clarity strengthens patent protection of SAR-bisPSMA 26 Nov 2021 3:08PM $0.880 $2.370 risen by 169.32%
$884 Results of Meeting 25 Nov 2021 2:40PM $0.945 $2.370 risen by 150.79%
$884 Managing Directors Presentation to Annual General Meeting 25 Nov 2021 9:46AM $0.900 $2.370 risen by 163.33%
$884 Chairman's Address to Shareholders 25 Nov 2021 9:40AM $0.900 $2.370 risen by 163.33%
$884 Quarterly Activity Report 18 Nov 2021 12:49PM $0.930 $2.370 risen by 154.84%

451 - 475 of 511 results

Page 19 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.